Everolimus plus exemestane as first-line therapy in HR(+), HER2(−) advanced breast cancer in BOLERO-2

The present exploratory analysis examined the efficacy, safety, and quality-of-life effects of everolimus (EVE) + exemestane (EXE) in the subgroup of patients in BOLERO-2 whose last treatment before study entry was in the (neo)adjuvant setting. In BOLERO-2, patients with hormone-receptor-positive (H...

Full description

Saved in:
Bibliographic Details
Main Authors: Beck, J. Thaddeus, Hortobagyi, Gabriel N., Campone, Mario, Lebrun, Fabienne, Deleu, Ines, Rugo, Hope S., Pistilli, Barbara, Masuda, Norikazu, Hart, Lowell, Melichar, Bohuslav, Dakhil, Shaker, Geberth, Matthias, Nunzi, Martina, Heng, Daniel Y. C., Brechenmacher, Thomas, El-Hashimy, Mona, Douma, Shyanne, Ringeisen, Francois, Piccart, Martine
Format: Artigo
Language:Inglês
Published: Springer US 2013
Subjects:
Clinical Trial
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3907668/
https://ncbi.nlm.nih.gov/pubmed/24362951
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-013-2814-5
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items